CD274 and neoplasm: Current strategies predominantly focus on single-dimensional biomarkers—including PD-L1 immunohistochemistry, tumor mutational burden (TMB), and TIL quantification—which exhibit variable predictive power across molecular subtypes and treatment lines (11).